Navigation Links
Breast Cancer Imaging Study Indicates Breast-Specific Gamma Imaging (BSGI) Is a Strong Adjunct Imaging Modality to Mammography and Ultrasound
Date:12/18/2007

Weigert study presented at Radiological Society of North America 93rd

Scientific Assembly and Annual Meeting

NEWPORT NEWS, Va., Dec. 18 /PRNewswire/ -- Study results recently presented at the Radiological Society of North America 93rd Scientific Assembly and Annual Meeting demonstrated the value of Breast-Specific Gamma Imaging (BSGI) as a strong adjunctive imaging modality to mammography and breast ultrasound. The study, performed by Dr. Jean Weigert, Director of Breast Imaging at Mandell and Blau MDs PC in New Britain, CT, demonstrated the very high predictive values of BSGI for identifying breast cancer.

Breast-Specific Gamma Imaging (BSGI) is molecular imaging of the breast, a novel physiologic approach in breast diagnostics that is performed with a high-resolution small field-of-view gamma camera and Tc-Sestamibi. According to Dr. Weigert, the radioisotope is taken up by cells with increased metabolic activity, such as the rapidly dividing cells in breast cancers; and areas of concern present at highly focalized areas of radiotracer uptake, or hotspots.

The study reviewed 512 women referred to BSGI due to an indeterminate mammogram and/or ultrasound. A history of breast cancer or new diagnosis of breast cancer as well as family history also warranted study. Additional mammography work-up, second-look ultrasound or MRI was used as needed to further evaluate areas of increased radiotracer uptake on BSGI.

Eighty-one percent of the patients had 6 to 24 month follow-up with no new findings. Ninety-seven biopsies were performed, of which 46 were positive and 51 were negative; five in patients with negative studies. In patients with newly diagnosed cancer, BSGI findings resulted in a change in surgical management in seven patients, identification of four occult contralateral cancers; and six patients underwent mastectomy due to discovery of more extensive disease. The smallest cancer identified was 5mm and no infiltrating lobular carcinomas were missed.

According to Dr. Weigert, Breast-Specific Gamma Imaging is a valuable technology that can help to diagnose unsuspected cancers and find greater extent of disease than may have been identified with mammography and ultrasound alone.

About BSGI with the Dilon 6800 Gamma Camera

Breast-Specific Gamma Imaging (BSGI) performed with the Dilon 6800, is a molecular breast imaging technique that can see lesions independent of tissue density and discover very early stage cancers. BSGI serves as a complementary diagnostic adjunct procedure to mammography and ultrasound for difficult-to-diagnose patients. With BSGI, the patient receives a radioactive tracing agent that is absorbed by all the cells in the body. Cancerous cells in the breast, due to their increased rate of metabolic activity, absorb a greater amount of the tracing agent than normal, healthy cells and generally appear as "hot spots" on the BSGI image.

BSGI is ideal for patients with mammograms that are difficult to interpret due to a variety of factors, such as: dense breast tissue, suspicious areas on a mammogram, lumps that can be felt but not seen with mammography or ultrasound, implants and breast augmentation, scarring from previous surgeries and for women with an increased risk of breast cancer diagnosis.

About Dilon Technologies

Dilon Technologies is bringing innovative new medical imaging products to market. Dilon's cornerstone product, the Dilon 6800, is a high-resolution, small field-of-view gamma camera, optimized to perform Breast-Specific Gamma Imaging (BSGI), a molecular breast imaging procedure that images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering BSGI to their patients, including: Cornell University Medical Center, New York; George Washington University Medical Center, Washington, D.C.; Northwestern Memorial Hospital, Chicago; and The Rose, Houston. For more information on Dilon Technologies please visit http://www.dilon.com.


'/>"/>
SOURCE Dilon Technologies
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Survival differences by race most apparent in advanced stages of breast cancer
2. MRI finds breast cancer before it becomes dangerous
3. Pathway links inflammation, angiogenesis and breast cancer
4. Drop in breast cancer incidence linked to hormone use, not mammograms
5. Breast cancer prevention practices vary across Canada
6. Eating junk food whilst pregnant and breastfeeding may lead to obese offspring
7. Acrylamide Wont Raise Breast Cancer Risk
8. New link between estrogen and breast cancer
9. Hypnosis Eases Pain of Breast Cancer Surgery
10. Discovery suggests location of genes for breast density, a strong risk factor for breast cancer
11. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... ... environs, is proud to announce an upgrade to the company's Yelp listing. Bay ... page on topics as diverse as Platelet Rich Plasma (PRP) therapy, hair transplantation ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... the lab became the world’s first to be ISO/IEC 17025:2005 INAB accredited for ... analysis. , ISO/IEC 17025:2005 is the globally recognised standard that sets out requirements ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... scheduling, and reporting for healthcare organizations. This comprehensive and customizable solution empowers ... process. StaffBridge technology improves staffing efficiency, maximizes resource allocation, collects critical reporting ...
(Date:2/25/2017)... ... February 25, 2017 , ... FCPX users now have the ... Pixel Film Studios. With ProSharpen Color users have total control over sharpening amount, sharpening ... color range. With color spectrum tools users can visually see the color range effected ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... education, networking and recognition opportunities as well as advocacy for the state and ... NJ on February 23. The Council's Innovation Forecast event highlights innovation throughout ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... Mass. , Feb. 27, 2017  Infinity Pharmaceuticals, ... at the Cowen and Company 37 th Annual ... p.m. ET in Boston, MA. ... on the Investors/Media section of Infinity,s website at ... following the event. About Infinity,Infinity is an ...
(Date:2/27/2017)... , Feb. 27, 2017  Impax Laboratories, Inc. (NASDAQ: IPXL ) ... conferences. Raymond James and Associates, 38 ... 6, 2017 in Orlando, FL. ... a.m. ET on March 7, 2017 in Boston, MA. ... March 16, 2017 in Miami, FL. ...
(Date:2/27/2017)... February 27, 2017 A recent research report ... marijuana market alone is expected to reach a value of $55.8 ... along with 28 states have legalized marijuana for medical uses. ... Florida , North Dakota , ... approved to use the drug in medical applications such as chemotherapies ...
Breaking Medicine Technology: